Victoria, Australia

Jonathan Cebon

This inventor holds 5 USPTO granted patents and 5 published patent applications and 2 EPO patents. Top assignees: Ludwig Institute for Cancer Research Limited, Pacific Edge Limited, Ucl Business Plc. Active years: 2013-2019.

USPTO Granted Patents = 5 

% Patents Active = 20.0

 

Average Co-Inventor Count = 4.2

ph-index = 2

Forward Citations = 9(Granted Patents)


Location History:

  • Heidelberg, AU (2013)
  • Clifton Hill, AU (2013 - 2014)
  • Victoria, AU (2017 - 2019)

Company Filing History:


Years Active: 2013-2019

Loading Chart...
Loading Chart...
5 patents (USPTO):Explore Patents

Title: The Innovative Journey of Jonathan Cebon

Introduction

Jonathan Cebon is an accomplished inventor based in Clifton Hill, Victoria, Australia. He has made significant contributions to the fields he has worked in, although he currently holds no patents. His career has been marked by his dedication to research and innovation.

Latest Patents

As of now, Jonathan Cebon has not registered any patents. This does not diminish his impact in the research community, as he has been involved in various innovative projects throughout his career.

Career Highlights

Jonathan has worked with notable organizations such as Pacific Edge Limited and the Ludwig Institute for Cancer Research Limited. His experience in these companies has allowed him to contribute to important research initiatives and advancements in medical science.

Collaborations

Throughout his career, Jonathan has collaborated with esteemed colleagues, including Michael Alan Black and Parry John Guilford. These partnerships have enriched his professional journey and fostered a collaborative environment for innovation.

Conclusion

Jonathan Cebon is a dedicated inventor whose work in research institutions has contributed to the advancement of science, despite not holding any patents. His collaborations and career experiences reflect his commitment to innovation and progress in his field.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…